06.01.10
Sirtris Pharmaceuticals, a subsidiary of GlaxoSmithKline, has halted a clinical trial evaluating a resveratrol-based drug after some patients suffered kidney damage. The phase 2 study was designed to evaluate the use of resveratrol as a stand alone treatment for multiple myeloma, as well as in conjunction with a cancer drug. Five of the 24 patients involved in the study developed kidney problems. The trial had been expected to run until December and involve up to 61 patients. The same drug, SRT501, was previously evaluated in three completed clinical trials in relation to type 2 diabetes.